GLENMARK PHARMACEUTICALS Fair Value
GLENMARK · Healthcare · Current price ₹2,455
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹823 | 31% ROE fading to 12% over ~10 yrs, on ₹372 book |
| Relative P/E | ₹1,887 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹636 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹2,392 | Street consensus 12-month target price |
Is GLENMARK PHARMACEUTICALS undervalued?
DocStoX estimates the fair value of GLENMARK PHARMACEUTICALS at ₹1,326 per share, versus the current market price of ₹2,455. That puts the stock about -46.0% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹823), Relative P/E (₹1,887), Graham floor (₹636), Analyst target (₹2,392). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹636 (bear) to ₹1,326 (base) to ₹2,392 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on GLENMARK PHARMACEUTICALS
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.